TwentyTwentyTweets
Tweets by 2020health-
Join 7,195 other subscribers
-
Recent Posts
Pages
Tag Archives: R&D
Threats to Mankind from Drug Resistant Bacteria and Viruses
The risk of an end to the human race may sound like science fiction. However, there are only a small number of threats that could theoretically lead to the extinction of mankind. The four main concerns that most experts share … Continue reading
Posted in Business, David Cameron, Drugs, Global Health, GPs, International, Most Significant, NHS, Pharma, Public Health, Rare conditions, Research, Vaccination
Tagged 2020health, AIDS, amoxicillin, Antibacterial, antibiotics, antiviral, Augmentin, bacteria, bacterial susceptibility, beta-lactam, beta-lactamase, bureaucracy, carpenem, cephalosporin, Ebola, end of mankind, Gilead, hepatitis, Hospitals, Human, hygiene, isolation, monobactam, NICE, pathogen, penicillin, plague, PPRS, prescribing, prevention, Prime Minister, Pseudomonas, R & D, R&D, rabies, Research, Research and development, resistance, sofosbuvir, Sovaldi, vaccine, virus, WHO
Comments Off on Threats to Mankind from Drug Resistant Bacteria and Viruses
Are pharmaceutical mega-mergers in the public interest?
The main reason for governments around the world to encourage the pharmaceutical industry is to support Research and Development – R&D – with a view to the discovery of new drugs of future benefit to mankind. Commercial pharmaceutical companies have played … Continue reading
Posted in Business, competition, Drugs, Innovation, International, Pharma, Policy, Research, Technology
Tagged 2020health, AstraZeneca, Beecham, Boots, competition, David Jack, Drugs, Glaxo, innovation, Keith Mansford, medicine, merger, Pfizer, pharmaceutical, R&D, Research, Sir David Jack, SmithKline, Smithkline Beecham, Tagamet, takeover
Leave a comment
Medical advisory body “NICE” should not spend too much time valuing drugs.
The UK National Institute for Health and Care Excellence (“NICE”) is currently holding a public consultation over its proposals for evaluating drugs. Drugs that are approved by NICE automatically become available for doctors to prescribe under the NHS throughout England … Continue reading
Posted in Business, CCGs, Commissioning, Department of Health, Drugs, Elderly, equality, Genetics, GPs, Health and Wellbeing, Health Bill, Health reform, Inequality, Innovation, Jeremy Hunt, NHS, NHS reforms, Patients, Pharma, Policy, Public Health, Research, Technology, Uncategorized, Wellbeing
Tagged 2020health, Clinical Commissioning Group, Commissioning, Department of Health, dose, elderly, General practitioner, government, GP, GPs, health, Health Bill, innovation, Jeremy Hunt, medicine, Medicines and Healthcare products Regulatory Agency, MHRA, National Health Service, National Institute for Health and Care Excellence, NHS, NICE, Old age, patient, Patients, pharmaceutical, PPRS, pricing, Proportionate QALY, Public Health, QALY, R&D, Research, value-based, value-based pricing
Leave a comment
Guest Blogspot: Negotiations with the UK Government over pharmaceutical pricing have achieved a good result for patients, the NHS and the industry.
The UK Government and the pharmaceutical industry shared many objectives throughout the recent drug pricing negotiations. For example, there was always broad agreement that: The total future drug bill needed to be affordable in the context of other spending in … Continue reading
Posted in Andrew Lansley, Business, Cancer, Department of Health, Drugs, Innovation, Jeremy Hunt, NHS, Patients, Pharma, Research, Smoking ban
Tagged 2020health, Andrew Lansley, Department of Health, Drugs, government, innovation, Jeremy Hunt, National Health Service, NHS, NICE, parallel export, parallel imporrt, patient, Patient Access Scheme, Patients, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing, VBP
1 Comment
Pharmaceutical companies must be free to determine their own research priorities: Lessons from Alzheimer’s Disease
Guest blog post from Barbara Arzymanow, Independent Healthcare Consultant Sir David Jack (1924-2011), one of history’s greatest pharmaceutical R&D directors under whom many important drugs were discovered, once told me that neither governments nor companies should overrule senior R&D management. … Continue reading
Posted in Business, Drugs, Innovation
Tagged acetylcholine, acetylcholinesterase, Alzheimer's, block-buster, British Biotech, C1-inh, cholinesterase, David Jack, glutamate, hub, innovation, marimastat, medicine, mental health, Neurochem, NICE, NMDA, pharmaceutical, R&D, Research, Sir David Jack
Leave a comment
Guest Blogspot: Waiting for Decisions on UK Pharmaceutical Pricing
Little has been heard over how confidential talks between the Government and the pharmaceutical industry are progressing towards the goal of having a new, voluntary UK drug pricing system in place in 2014. In the eyes of the pharmaceutical companies … Continue reading
Posted in Andrew Lansley, Business, Children, Commissioning, David Cameron, Department of Health, Drugs, Emerging technologies, equality, Health and Wellbeing, Innovation, Jeremy Hunt, Uncategorized, Wellbeing
Tagged 2020health, Andrew Lansley, Bowel Cancer UK, Cancer Research UK, Drugs, government, innovation, medicine, Multiple Sclerosis Society, pharmaceutical, R&D, value-based, value-based pricing
1 Comment
Guest Blogspot: Think carefully about value-based drug pricing in the UK and let common sense prevail.
David Cameron and Jeremy Hunt share an important skill. They both have firsts from Oxford in Politics, Philosophy and Economics (PPE). I am not the greatest fan of this course because I would like to see more scientists, engineers and … Continue reading
Posted in Business, competition, David Cameron, Department of Health, Drugs, Election, Jeremy Hunt, NHS, Patients, Pharma, Policy, Primary Care
Tagged 2020health, block-buster, competition, David Cameron, demand, Department of Health, drug pricing system, Drugs, elderly, GP, GPs, Health Bill, innovation, medicine, National Health Service, NHS, NICE, parallel exports, parallel imports, patient, Patients, pharmaceutical, Philosophy and Economics, Politics, PPE, PPRS, pricing, quality of life, R&D, reference price, Research, value-based, value-based pricing, VBP
Leave a comment
Guest Blogspot: The Pharmaceutical Industry – Friend or Foe?
Recent months have seen publicity over examples of disgraceful behaviour by pharmaceutical companies. The question arises as to whether the failings have been rare and exceptional or whether they are indicative of generally low moral standards in the industry. Pharmaceutical … Continue reading
Posted in Alcohol, Business, Drugs, Finance, GPs, Information, NHS, Obesity, Research
Tagged 2020health, Abbott, alcohol, AstraZeneca, bribes, criminal, dishonest, Drugs, General practitioner, government, GP, GPs, GSK, innovation, Kuno Sommer, law breaking, life expectancy, Lilly, medicine, misleading, National Health Service, NHS, Obesity, patient, Patients, Paxil, Pfizer, pharmaceutical, practolol, pricing, R&D, Research, Responsibility in healthcare, Seroquel, thalidomide, tobacco, Wellbutrin, wrongdoing, Zhen Xiaoyu
Leave a comment
Guest Blogspot: A wrong decision on UK drug pricing could seriously undermine all the good work that HM Treasury and the Department for Business, Innovation and Skills have done to encourage the UK pharmaceutical industry.
The recent local elections highlight the political dangers ahead. The current UK coalition government has lost popularity through decisions that do not all relate to austerity measures. Shortly after the General Election Andrew Lansley’s plans to increase the say of … Continue reading
Posted in Andrew Lansley, Business, Department of Health, Drugs, Election, Global Health, Health Bill, NHS, Patient choice, Patients, Pharma, Policy, Research, Technology
Tagged 2020health, Andrew Lansley, AstraZeneca, Department of Health, Drugs, GlaxoSmithKline, GSK, health, Health Bill, innovation, medicine, National Health Service, NHS, NICE, patient, Patients, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing
Leave a comment
Guest Blogspot: The NHS needs outstanding management as well as a legal framework, for example, to unlock the potential of the property portfolio.
The potential for improved efficiency in delivering effective healthcare within the framework of the Health and Social Care Act 2012 is enormous. However, there will be no benefit without the management skills needed to take up the challenges. Many future … Continue reading
Posted in CCGs, Commissioning, competition, Department of Health, Election, Employment, GPs, Health Bill, Health Team, Healthcare, Hospitals, Information, NHS, Nursing, Uncategorized
Tagged 2020health, Commissioning, Department of Health, Drugs, elderly, General practitioner, GPs, health, Health Bill, National Health Service, NHS, Old age, outcomes, R&D, Responsibility in healthcare, Social Care
2 Comments
2020health's Blog 
You must be logged in to post a comment.